May 29, 2020
Surrozen and Lonza Announce Partnership for the Development and Manufacture of Surrozen’s Novel Wnt Activating Antibodies
Surrozen is developing first-in-class bi-specific antibodies that selectively stimulate tissue regeneration
Lonza to provide cell line development, drug substance and drug product process development and cGMP manufacturing, and regulatory support for IND filing
Lonza’s Light Path™ cell line development program will be tailored enabling Surrozen to prepare for their IND filing